Similac, Pediasure Drive Abbott’s Ross Sales In 2007
• By Rebekah Moan
Similac, PediaSure and the launch of NutriPals bars and shakes drove sales by Abbott Laboratories' Ross U.S. Nutritionals unit up 3 percent to $624 million in its fourth quarter, according to Abbott President and COO Rick Gonzalez
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.
Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?